Normative MRI modelling identifies critical brain volume deviations associated with disability in multiple sclerosis
Do brain scans show more warning signs of disability in multiple sclerosis than in healthy people?
This observational cohort study applied a normative model trained on 62,444 healthy MRI datasets to scans from 362 people with multiple scle…
Brain scans reveal that people with multiple sclerosis have more critical volume deviations than healthy individuals, directly linked to hig…
High-dose melatonin linked to hepatotoxicity in small PP-MS trial, prompting early halt
High-dose melatonin trial halted after liver safety concerns in MS patients
A phase I/II RCT of 8 patients with PP-MS on stable ocrelizumab found that adjunctive high-dose oral melatonin (300 mg/day) was associated w…
A high-dose melatonin trial for multiple sclerosis stopped early after three of four patients developed mild liver injury, though the issue …
CSF proteomic signatures show potential for MS diagnosis and prognosis in cohort study
Could a spinal fluid test predict how multiple sclerosis will progress?
A multicentric cohort study of 120 patients with multiple sclerosis, clinically isolated syndrome, and healthy controls analyzed cerebrospin…
A spinal fluid test with ten proteins could predict multiple sclerosis progression, showing promise for forecasting disease activity up to f…
Online behavioral intervention increases physical activity and improves depression in newly diagnosed multiple sclerosis
Can online coaching help people newly diagnosed with MS get moving and feel better?
A pilot randomized controlled trial in 50 people newly diagnosed with MS found that a 16-week COM-B-based online behavioral intervention sig…
Online coaching helped newly diagnosed MS patients add 11 minutes of daily activity, feel less depressed, and improve mental health quality …
FDA Approves Kesimpta (ofatumumab) for Relapsing Forms of Multiple Sclerosis in Adults
The FDA approved a new monthly self-injection drug for multiple sclerosis
The FDA has approved Kesimpta, a CD20-directed cytolytic antibody, for the treatment of relapsing forms of multiple sclerosis in adults.
The FDA approved Kesimpta, a new monthly self-injection for adults with relapsing forms of multiple sclerosis.
Neuromuscular electrostimulation plus swallowing therapy may benefit dysphagia in severely disabled MS patients
Can electrical stimulation help people with MS swallow more easily?
A randomized controlled trial in 101 people with MS and dysphagia found both traditional swallowing therapy plus neuromuscular electrostimul…
For people with advanced multiple sclerosis, adding gentle electrical stimulation to standard swallowing therapy led to significantly greate…
Percutaneous balloon compression shows initial pain relief in multiple sclerosis-related trigeminal neuralgia
Balloon compression procedure shows initial pain relief for MS-related facial pain
A systematic review and meta-analysis of 12 studies involving 386 patients with MS-related trigeminal neuralgia found percutaneous balloon c…
A balloon compression procedure offers immediate pain relief for most people with severe facial pain caused by multiple sclerosis, though lo…
Ponesimod Shows Sustained Efficacy and Safety in RMS Over 5 Years
Could Ponesimod Change the Game for Multiple Sclerosis Patients?
In a 5-year extension of the OPTIMUM study, ponesimod 20 mg maintained a lower ARR (0.143) compared to teriflunomide switchers (0.184).
After five years, nearly half of people taking ponesimod for multiple sclerosis had no relapses, offering more stable lives with fewer unexp…
Questions about Multiple Sclerosis
How does oral cladribine change immune cells in relapsing multiple sclerosis?
Oral cladribine depletes certain B and T cells in the blood and CSF, reduces microglial activation, and allows recovery of naive B cells, which may help control relapsing MS.
Full answer →What active therapeutic interventions are available for Multiple Sclerosis patients in inpatient rehabilitation?
Inpatient rehabilitation for MS includes gait training, robot-assisted therapy, strength, balance, and aerobic exercises, all showing mobility and fatigue benefits.
Full answer →Are CAR-T cell therapies currently being used to treat Multiple Sclerosis according to recent reviews?
CAR-T cell therapies are not yet approved for MS but are being tested in clinical trials, with early results showing safety and potential benefit.
Full answer →Can aerobic or strength training help reduce fatigue in people with Multiple Sclerosis?
Yes, both aerobic and strength training can reduce fatigue in people with multiple sclerosis, with studies showing similar benefits from each modality.
Full answer →How much has the incidence of Multiple Sclerosis in women of childbearing age increased since 1990?
The incidence of Multiple Sclerosis in women of childbearing age has increased by 48% from 1990 to 2021, according to a global burden of disease study.
Full answer →What is the success rate for pain relief in Multiple Sclerosis patients treated with microvascular decompression?
Microvascular decompression for trigeminal neuralgia in multiple sclerosis patients has a long-term pain-free success rate of about 30.2%, based on a 2024 systematic review.
Full answer →